[{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"Prostanoid FP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1.6399999999999999,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"Prostanoid FP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1.6399999999999999,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Epicord","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Jagdale Industries","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Isoxsuprine Hydrochloride","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bharat Serums & Vaccines ltd \/ Bharat Serums & Vaccines ltd","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Bharat Serums & Vaccines ltd"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Recombinant-Human Follicle Stimulating Hormone","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Bharat Serums & Vaccines ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (carboprost tromethamine), which is indicated for the treatment of post partum haemorrhage.

                          Product Name : Endoprost

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 23, 2024

                          Lead Product(s) : Carboprost Tromethamine

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Mankind Pharma

                          Deal Size : $1,637.3 million

                          Deal Type : Acquisition

                          blank

                          02

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.

                          Product Name : Endoprost

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          July 26, 2024

                          Lead Product(s) : Carboprost Tromethamine

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Mankind Pharma

                          Deal Size : $1,640.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, Hucog 5000 HP, AntiD among others.

                          Product Name : Tidilan

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          April 05, 2022

                          Lead Product(s) : Isoxsuprine Hydrochloride

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Jagdale Industries

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Recombinant-Human Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          March 04, 2022

                          Lead Product(s) : Recombinant-Human Follicle Stimulating Hormone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Leuprolide Acetate is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 04, 2021

                          Lead Product(s) : Leuprolide Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Epicord is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 08, 2021

                          Lead Product(s) : Epicord

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 09, 2020

                          Lead Product(s) : Urinastatin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank